Albumin-conjugated GHRH analog providing days-long elevation of GH and IGF-1 — distinct from the pulsatile pattern of native GHRH.
Reference facts
- Also known as
- CJC-1295 DAC, Drug Affinity Complex GHRH
- Category
- Growth Hormone & Ghrelin
- Mechanism of action
- Albumin-conjugated GHRH analog providing days-long elevation of GH and IGF-1 — distinct from the pulsatile pattern of native GHRH.
- Targets
- GHRHR
- Indications under research or approved
- Off-label research
- Regulatory status (reference entry)
- Not FDA-approved
- Half-life
- ~6–8 days (albumin-bound)
- Sequence
- YADAIFTNSYRKVLGQLSARKLLQDIMSR
- Sequence notes
- CJC-1295 backbone with maleimidopropionyl-Lys30 that covalently conjugates to circulating albumin in vivo, extending half-life to ~6 days.
- Molecular weight (Da)
- 3647
- First reported
- 2005
Primary References
Explore research articles about CJC-1295 with DAC
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.